Everest Medicines Limited
HKEX:1952.HK
22.9 (HKD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 523.063 | 490.788 | 2,640.053 | 4,481.122 | 106.061 | 183.503 |
| Short Term Investments
| 1,826.628 | 1,160.588 | 0 | 2.084 | 0.161 | 0.392 |
| Cash and Short Term Investments
| 2,349.691 | 1,651.376 | 2,640.053 | 4,481.122 | 106.061 | 183.503 |
| Net Receivables
| 49.858 | 1,751.102 | 47.378 | 0 | 0 | 0 |
| Inventory
| 18.944 | 11.637 | 0.447 | 0 | 0 | 0 |
| Other Current Assets
| 0.916 | 0.027 | 0.05 | 0.909 | 0.159 | 0.15 |
| Total Current Assets
| 2,507.613 | 3,414.142 | 2,687.928 | 4,496.409 | 131.153 | 209.815 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 651.451 | 690.517 | 253.795 | 86.695 | 46.077 | 18.678 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 2,556.871 | 2,412.34 | 2,850.157 | 2,041.335 | 1,663.449 | 493.461 |
| Goodwill and Intangible Assets
| 2,556.871 | 2,412.34 | 2,850.157 | 2,041.335 | 1,663.449 | 493.461 |
| Long Term Investments
| 48.93 | -1,071.346 | 830.403 | 845.697 | 34.881 | 0 |
| Tax Assets
| -0.619 | 1,071.346 | -830.403 | -845.697 | -34.881 | 0 |
| Other Non-Current Assets
| 8.526 | 97.739 | 853.943 | 852.742 | 296.261 | 1.218 |
| Total Non-Current Assets
| 3,265.159 | 3,200.596 | 3,957.895 | 2,980.772 | 2,005.787 | 513.357 |
| Total Assets
| 5,772.772 | 6,614.738 | 6,645.823 | 7,477.181 | 2,136.94 | 723.172 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 48.893 | 44.495 | 54.251 | 40.725 | 40.057 | 1.646 |
| Short Term Debt
| 41.316 | 444.408 | 28.251 | 19.015 | 10.543 | 5.82 |
| Tax Payables
| 3.72 | 5.962 | 4.977 | 3.674 | 1.499 | 0 |
| Deferred Revenue
| 27.935 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 181.983 | 381.122 | 187.764 | 127.174 | 453.273 | 152.459 |
| Total Current Liabilities
| 300.127 | 870.025 | 270.266 | 186.914 | 503.873 | 159.925 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 469.31 | 59.307 | 456.783 | 428.316 | 30.216 | 10.918 |
| Deferred Revenue Non-Current
| 6.053 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 22.561 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 6.053 | 30.923 | 26.778 | 20.88 | 2,463.933 | 1,499.898 |
| Total Non-Current Liabilities
| 503.977 | 90.23 | 483.561 | 449.196 | 2,494.149 | 1,510.816 |
| Total Liabilities
| 804.104 | 960.255 | 753.827 | 636.11 | 2,998.022 | 1,670.741 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 0.219 | 0.211 | 0.202 | 0.198 | 0.017 | 0.002 |
| Retained Earnings
| -9,016.481 | -8,172.018 | -7,924.735 | -6,916.016 | -1,257.851 | -1,043.339 |
| Accumulated Other Comprehensive Income/Loss
| 13,984.931 | 13,826.293 | 13,875.236 | 13,756.889 | 396.752 | -5.282 |
| Other Total Stockholders Equity
| -0.001 | -0.003 | -58.707 | 0 | 0 | 101.05 |
| Total Shareholders Equity
| 4,968.668 | 5,654.483 | 5,891.996 | 6,841.071 | -861.082 | -947.569 |
| Total Equity
| 4,968.668 | 5,654.483 | 5,891.996 | 6,841.071 | -861.082 | -947.569 |
| Total Liabilities & Shareholders Equity
| 5,772.772 | 6,614.738 | 6,645.823 | 7,477.181 | 2,136.94 | 723.172 |